Results 41 to 50 of about 22,196 (255)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine

BMC Cardiovascular Disorders, 2021
Background Ergot-derived dopamine agonists are thought to induce fibrotic changes in cardiac valve leaflets. We sought to determine the incidence of heart valve disease in women treated with bromocriptine compared with age and sex matched controls from ...
Marianne F. Clausen, Rasmus Rørth, Christian Torp-Pedersen, Lucas Malta Westergaard, Peter E. Weeke, Gunnar Gislason, Lars Køber, Emil Fosbøl, Søren Lund Kristensen   +8 more
doaj   +1 more source

Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson's disease

Disease Models & Mechanisms, 2016
The effect of bromocriptine, a dopamine agonist, administered in the form of bromocriptine alginate nanocomposite (BANC) was studied on Parkinson's disease (PD) model flies.
Y. Siddique, Wasi Khan, A. Fatima, Smita Jyoti, Saba Khanam, Falaq Naz, Rahul, Fahad Ali, B. Singh, A. Naqvi   +9 more
semanticscholar   +1 more source

Impact of ergot alkaloid and steroidal implant on whole-body protein turnover and expression of mTOR pathway proteins in muscle of cattle

Frontiers in Veterinary Science, 2023
IntroductionHolstein steers (n = 32) were used to determine if the ergot analog, bromocriptine decreases muscle protein synthesis through inhibitory action on the mTOR pathway via a direct effect on signal proteins, and if these negative effects can be ...
Taylor D. Ferguson, Caroline M. M. Loos, Eric S. Vanzant, Kristine L. Urschel, James L. Klotz, Kyle R. McLeod   +5 more
doaj   +1 more source

Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells

Cancer research and treatment : official journal of Korean Cancer Association, 2016
Purpose Prolactinoma (prolactin-secreting pituitary adenoma) is one of the most common estrogen-related functional pituitary tumors. As an agonist of the dopamine D2 receptor, bromocriptine is used widely to inhibit prolactinoma progression. On the other
Jinxiang Huang, Fenglin Zhang, Lei Jiang, G. Hu, Wei Sun, Chenran Zhang, Xuehua Ding   +6 more
semanticscholar   +1 more source

Cannabinoid-deficient Benin republic hemp (Cannabis sativa L.) improves semen parameters by reducing prolactin and enhancing anti-oxidant status

BMC Complementary and Alternative Medicine, 2019
Background Nigerian Cannabis sativa (hemp) causes male gonadotoxicity by inducing hyperprolactinemia, down-regulation of hypothalamic-pituitary-testicular axis, and oxidative stress.
Abdullateef Isiaka Alagbonsi, Luqman Aribidesi Olayaki, Halimat Amin Abdulrahim, Thomson Sijuade Adetona, Gbemileke Tobiloba Akinyemi   +4 more
doaj   +1 more source

Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy

Clinical Research in Cardiology, 2015
BackgroundPeripartum cardiomyopathy (PPCM) is an idiopathic heart disease that develops in the last month of pregnancy and/or the first months following delivery in previously healthy women and may lead to acute heart failure.
A. Haghikia, E. Podewski, D. Berliner, K. Sonnenschein, D. Fischer, C. Angermann, M. Böhm, Philipp Röntgen, J. Bauersachs, D. Hilfiker-Kleiner   +9 more
semanticscholar   +1 more source

The regulatory effect of bromocriptine on cardiac hypertrophy by prolactin and D2 receptor modulation

Clinical and Experimental Hypertension, 2020
Background Bromocriptine, a dopamine agonist, used for the treatment of hyperprolactinemia, type 2 diabetes, ovarian hyper-stimulation syndrome, has also effects on the cardiac remodeling process, but the mechanism of action is unknown.
Karla Aidee Aguayo-Cerón, Claudia Camelia Calzada-Mendoza, Enrique Méndez-Bolaina, Rodrigo Romero-Nava, María Esther Ocharan-Hernández   +4 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2015
In the article Gaziano et al, “Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects,” which published online October 12, 2012, and appeared in the October ...
L. Wilkins
semanticscholar   +1 more source

A peripartum cardiomyopathy case treated with bromocriptine

Turkish Journal of Internal Medicine, 2021
Introduction: Peripartum cardiomyopathy is a rare disease that is difficult to diagnose and treat. Clinical findings are similar with heart failure. New treatments are needed in addition to the treatment of heart failure.
Dilek Yeşilbursa, Şeyda Günay, Naile Bolca Topal, Osman Akın Serdar, Sümeyye Güllülü   +4 more
doaj   +1 more source